European Radiology

, Volume 13, Issue 8, pp 1849–1858

Dynamic contrast-enhanced MR imaging in monitoring response to isolated limb perfusion in high-grade soft tissue sarcoma: initial results

  • Catherina S. P. van Rijswijk
  • Maartje J. A. Geirnaerdt
  • Pancras C. W. Hogendoorn
  • Johannes L. Peterse
  • Frits van Coevorden
  • Antonie H. M. Taminiau
  • Rob A. E. M. Tollenaar
  • Bin B. R. Kroon
  • Johan L. Bloem
Musculoskeletal

Abstract

The objective of this study was to evaluate whether dynamic contrast-enhanced MR imaging can determine tumor response and localize residual viable tumor after isolated limb perfusion (ILP) chemotherapy in soft tissue tumors. Twelve consecutive patients, with histologically proven high-grade soft tissue sarcoma, prospectively underwent non-enhanced MR and dynamic contrast-enhanced MR imaging before and after ILP. Tumor volume was measured on non-enhanced MR images. The temporal change of signal intensity in a region of interest on dynamic contrast-enhanced MR images was plotted against time. Start, pattern, and progression of enhancement were recorded. Histopathologic response was defined as complete response if no residual viable tumor was present, partial remission if <50% viable tumor was present, and no change if ≥50% viable tumor was present in the resection specimen. Resected specimens for correlation with histopathology were available for 10 patients; 5 patients had partial remission and 5 had no change. Volume measurements correctly predicted tumor response in 6 of 10 patients. Dynamic contrast-enhanced MR correctly predicted tumor response in 8 of 10 patients. Early rapidly progressive enhancement correlated histologically with residual viable tumor. Late and gradual, or absence of enhancement, was associated with necrosis, predominantly centrally located, or granulation tissue. These preliminary results show that dynamic contrast-enhanced MR imaging offers potential for non-invasive monitoring of response to isolated limb perfusion in soft tissue sarcomas due to identification of residual areas of viable tumor and subsequently may provide clinically useful information with regards to timing and planning of additional surgery. Further prospective studies in a larger patient population is warranted.

Keywords

Soft tissue Neoplasms Magnetic resonance Dynamic contrast enhancement Therapy monitoring Isolated limb perfusion 

References

  1. 1.
    Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182–1186PubMedGoogle Scholar
  2. 2.
    Denekamp J (1993) Review article: angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br J Radiol 66:181–196PubMedGoogle Scholar
  3. 3.
    Lienard D, Ewalenko P, Delmotte JJ, Renard N, Lejeune FJ (1992) High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 10:52–60PubMedGoogle Scholar
  4. 4.
    Eggermont AM, Schraffordt Koops H, Klausner JM et al. (1996) Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg 224:756–764PubMedGoogle Scholar
  5. 5.
    Eggermont AM, Schraffordt Koops H, Lienard D et al. (1996) Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol 14:2653–2665PubMedGoogle Scholar
  6. 6.
    Renard N, Lienard D, Lespagnard L, Eggermont AM, Heimann R, Lejeune F (1994) Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumour necrosis factor alpha (rTNF alpha). Int J Cancer 57:656–663PubMedGoogle Scholar
  7. 7.
    Issakov J, Merimsky O, Gutman M et al. (2000) Hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan in advanced soft-tissue sarcomas: histopathological considerations. Ann Surg Oncol 7:155–159PubMedGoogle Scholar
  8. 8.
    Olieman AF, van Ginkel RJ, Hoekstra HJ, Mooyaart EL, Molenaar WM, Schraffordt Koops H (1997) Angiographic response of locally advanced soft-tissue sarcoma following hyperthermic isolated limb perfusion with tumor necrosis factor. Ann Surg Oncol 4:64–69PubMedGoogle Scholar
  9. 9.
    Carrasco CH, Charnsangavej C, Raymond AK et al. (1989) Osteosarcoma: angiographic assessment of response to preoperative chemotherapy. Radiology 170:839–842Google Scholar
  10. 10.
    Delorme S, Knopp MV (1998) Non-invasive vascular imaging: assessing tumour vascularity. Eur Radiol 8:517–527PubMedGoogle Scholar
  11. 11.
    Erlemann R, Sciuk J, Bosse A et al. (1990) Response of osteosarcoma and Ewing sarcoma to preoperative chemotherapy: assessment with dynamic and static MR imaging and skeletal scintigraphy. Radiology 175:791–796PubMedGoogle Scholar
  12. 12.
    Erlemann R (1993) Dynamic, gadolinium-enhanced MR imaging to monitor tumor response to chemotherapy. Radiology 186:904–905PubMedGoogle Scholar
  13. 13.
    Hanna SL, Parham DM, Fairclough DL, Meyer WH, Le AH, Fletcher BD (1992) Assessment of osteosarcoma response to preoperative chemotherapy using dynamic FLASH gadolinium-DTPA-enhanced magnetic resonance mapping. Invest Radiol 27:367–373PubMedGoogle Scholar
  14. 14.
    Reddick WE, Bhargava R, Taylor JS, Meyer WH, Fletcher BD (1995) Dynamic contrast-enhanced MR imaging evaluation of osteosarcoma response to neoadjuvant chemotherapy. J Magn Reson Imaging 5:689–694PubMedGoogle Scholar
  15. 15.
    van der Woude HJ, Bloem JL, Verstraete KL, Taminiau AH, Nooy MA, Hogendoorn PC (1995) Osteosarcoma and Ewing's sarcoma after neoadjuvant chemotherapy: value of dynamic MR imaging in detecting viable tumor before surgery. Am J Roentgenol 165:593–598Google Scholar
  16. 16.
    Shapeero LG, Henry-Amar M, Vanel D (1992) Response of osteosarcoma and Ewing sarcoma to preoperative chemotherapy: assessment with dynamic and static MR imaging and skeletal scintigraphy. Invest Radiol 27:989–991PubMedGoogle Scholar
  17. 17.
    Creech O Jr, Krementz E (1966) Techniques of regional perfusion. Surgery 60:938–947PubMedGoogle Scholar
  18. 18.
    Verstraete KL, Achten E, Dierick A (1992) Dynamic contrast-enhanced MRI of musculo-skeletal neoplasms: different types and slopes of time—intensity curves (abstr). In: Books of abstracts. Society of Magnetic Resonance in Medicine 1992. Society of Magnetic Resonance in Medicine, Berkeley, CaliforniaGoogle Scholar
  19. 19.
    Clamon G, Clamon L (1993) Relationship between tumor area, tumor volume, and criteria of response in clinical trials. J Clin Oncol 11:1005Google Scholar
  20. 20.
    De Schepper AM, Parizel PM, De Beuckeleer L, Vanhoenacker F (2001) Imaging of soft tissue tumors, 2nd edn. Springer, Berlin Heidelberg New YorkGoogle Scholar
  21. 21.
    van der Woude HJ, Verstraete KL, Hogendoorn PC, Taminiau AH, Hermans J, Bloem JL (1998) Musculoskeletal tumors: Does fast dynamic contrast-enhanced subtraction MR imaging contribute to the characterization? Radiology 208:821–828PubMedGoogle Scholar
  22. 22.
    Verstraete KL, De Deene Y, Roels H, Dierick A, Uyttendaele D, Kunnen M (1994) Benign and malignant musculoskeletal lesions: dynamic contrast-enhanced MR imaging: parametric "first-pass" images depict tissue vascularization and perfusion. Radiology 192:835–843PubMedGoogle Scholar
  23. 23.
    Eroglu A, Kocaoglu H, Demirci S, Akgul H (2000) Isolated limb perfusion with cisplatin and doxorubicin for locally advanced soft tissue sarcoma of an extremity. Eur J Surg Oncol 26:213–221CrossRefPubMedGoogle Scholar
  24. 24.
    Moertel CG, Hanley JA (1976) The effect of measuring error on the results of therapeutic trials in advanced cancer. Cancer 38:388–394PubMedGoogle Scholar
  25. 25.
    Fletcher BD, Hanna SL, Fairclough DL, Gronemeyer SA (1992) Pediatric musculoskeletal tumors: use of dynamic, contrast-enhanced MR imaging to monitor response to chemotherapy. Radiology 184:243–248PubMedGoogle Scholar
  26. 26.
    Schmidt RA, Conrad EU III, Collins C, Rabinovitch P, Finney A (1993) Measurement and prediction of the short-term response of soft tissue sarcomas to chemotherapy. Cancer 72:2593–2601PubMedGoogle Scholar
  27. 27.
    Panicek DM, Casper ES, Brennan MF, Hajdu SI, Heelan RT (1991) Hemorrhage simulating tumor growth in malignant fibrous histiocytoma at MR imaging. Radiology 181:398–400PubMedGoogle Scholar
  28. 28.
    Kettelhack C, Wickede M, Vogl T, Schneider U, Hohenberger P (2002) 31Phosphorus-magnetic resonance spectroscopy to assess histologic tumor response noninvasively after isolated limb perfusion for soft tissue tumors. Cancer 94:1557–1564CrossRefPubMedGoogle Scholar
  29. 29.
    De Schepper AM, De Beuckeleer L, Vandevenne J, Somville J (2000) Magnetic resonance imaging of soft tissue tumors. Eur Radiol 10:213–223PubMedGoogle Scholar
  30. 30.
    Taylor JS, Tofts PS, Port R et al. (1999) MR imaging of tumor microcirculation: promise for the new millennium. J Magn Reson Imaging 10:903–907CrossRefPubMedGoogle Scholar
  31. 31.
    Lang P, Vahlensieck M, Matthay KK et al. (1996) Monitoring neovascularity as an indicator to response to chemotherapy in osteogenic and Ewing sarcoma using magnetic resonance angiography. Med Pediatr Oncol 26:329–333CrossRefPubMedGoogle Scholar
  32. 32.
    Shapeero LG, Vanel D, Verstraete KL, Bloem JL (1999) Dynamic contrast-enhanced MR imaging for soft tissue sarcomas. Semin Musculoskelet Radiol 3:101–114PubMedGoogle Scholar
  33. 33.
    Shapeero LG, Vanel D, Verstraete KL, Bloem JL (2002) Fast magnetic resonance imaging with contrast for soft tissue sarcoma viability. Clin Orthop 2002:212–227Google Scholar
  34. 34.
    Jones DN, McCowage GB, Sostman HD et al. (1996) Monitoring of neoadjuvant therapy response of soft-tissue and musculoskeletal sarcoma using fluorine-18-FDG PET. J Nucl Med 37:1438–1444PubMedGoogle Scholar
  35. 35.
    van Ginkel RJ, Hoekstra HJ, Pruim J et al. (1996) FDG-PET to evaluate response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcoma. J Nucl Med 37:984–990PubMedGoogle Scholar
  36. 36.
    van Ginkel RJ, Kole AC, Nieweg OE et al. (1999) L-[1–11C]-tyrosine PET to evaluate response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcoma and skin cancer. J Nucl Med 40:262–267PubMedGoogle Scholar
  37. 37.
    Sijens PE, Eggermont AM, van Dijk PV, Oudkerk M (1995) 31P magnetic resonance spectroscopy as predictor of clinical response in human extremity sarcomas treated by single dose TNF-alpha+melphalan isolated limb perfusion. NMR Biomed 8:215–224PubMedGoogle Scholar
  38. 38.
    Redmond OM, Bell E, Stack JP et al. (1992) Tissue characterization and assessment of preoperative chemotherapeutic response in musculoskeletal tumors by in vivo 31P magnetic resonance spectroscopy. Magn Reson Med 27:226–237PubMedGoogle Scholar
  39. 39.
    Brasch RC, Li KC, Husband JE et al. (2000) In vivo monitoring of tumor angiogenesis with MR imaging. Acad Radiol 7:812–823PubMedGoogle Scholar
  40. 40.
    Egmont-Petersen M, Hogendoorn PC, van der Geest RJ et al. (2000) Detection of areas with viable remnant tumor in postchemotherapy patients with Ewing's sarcoma by dynamic contrast-enhanced MRI using pharmacokinetic modeling. Magn Reson Imaging 18:525–535CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2003

Authors and Affiliations

  • Catherina S. P. van Rijswijk
    • 1
  • Maartje J. A. Geirnaerdt
    • 2
  • Pancras C. W. Hogendoorn
    • 3
  • Johannes L. Peterse
    • 4
  • Frits van Coevorden
    • 5
  • Antonie H. M. Taminiau
    • 6
  • Rob A. E. M. Tollenaar
    • 7
  • Bin B. R. Kroon
    • 5
  • Johan L. Bloem
    • 1
  1. 1.Department of RadiologyLeiden University Medical CenterLeidenThe Netherlands
  2. 2.Department of RadiologyNetherlands Cancer Institute Antoni van Leeuwenhoek Hospital AmsterdamThe Netherlands
  3. 3.Department of PathologyLeiden University Medical CenterLeidenThe Netherlands
  4. 4.Department of PathologyNetherlands Cancer Institute, Antoni van Leeuwenhoek HospitalAmsterdamThe Netherlands
  5. 5.Department of SurgeryNetherlands Cancer Institute, Antoni van Leeuwenhoek HospitalAmsterdamThe Netherlands
  6. 6.Department of Orthopedic SurgeryLeiden University Medical CenterLeidenThe Netherlands
  7. 7.Department of SurgeryLeiden University Medical CenterLeidenThe Netherlands

Personalised recommendations